Myfembree Reviews for Fibroids and Endometriosis

Myfembree (relugolix/estradiol/norethindrone acetate) has strong clinical trial data behind it, with roughly three out of four women in pivotal studies seeing meaningful relief from heavy menstrual bleeding caused by uterine fibroids or from endometriosis-related pain. That said, real-world experience is more nuanced than headline trial results, and what the drug does well, what it does not do, and what trade-offs come with it are worth understanding before starting treatment.

What Myfembree Actually Does in Your Body

Myfembree is a once-daily pill that combines three active ingredients. The core component, relugolix, blocks the hormone signals that drive your ovaries to produce estrogen and progesterone. Without those hormones fueling fibroid growth and endometrial tissue activity, heavy bleeding slows and pain decreases. The catch is that driving estrogen too low causes problems of its own, including bone thinning and hot flashes. That is why the pill also contains low doses of estradiol and norethindrone acetate, a form of progestin, to keep estrogen levels in a middle range where symptoms improve but the body does not tip into a menopause-like state.¹ This “add-back” approach is the defining design feature of the drug and the reason it can be used for longer stretches than older GnRH-based treatments that suppressed estrogen without replacing any of it.

How Well It Controls Heavy Bleeding from Fibroids

The strongest evidence comes from the two phase 3 LIBERTY trials, which enrolled women with fibroid-related heavy menstrual bleeding. In both studies, Myfembree substantially reduced bleeding compared to placebo and improved a range of other fibroid symptoms.² A subgroup analysis of the European participants in those same trials put the response rate at about 85% for the treatment group versus 19% for placebo, with statistically significant improvements in bleeding volume, pain, symptom severity, pelvic discomfort, and quality of life.³

Quality-of-life scores tell a similar story. In the long-term extension of the LIBERTY trials, women who had anemia at baseline saw symptom severity scores drop by about 39 points and fatigue scores drop by about 32 points on validated scales, while overall health-related quality-of-life scores climbed by roughly 42 points.⁴ For women whose daily lives have been shaped by unpredictable heavy periods and exhaustion, those shifts can feel transformative.

How Well It Manages Endometriosis Pain

Myfembree also has approval for endometriosis-associated pain, based on the two SPIRIT trials. About 75% of women on the drug met the definition for a meaningful reduction in period pain (dysmenorrhea), compared with roughly 27–30% on placebo. For non-menstrual pelvic pain, around 59–66% of treated women responded, versus 40–43% on placebo.⁵ The gap between drug and placebo was wider for period pain than for non-menstrual pelvic pain, which makes sense given that the drug’s main lever is suppressing the hormonal cycle driving menstruation.

The speed of relief matters to anyone living with endometriosis pain. Extension trial data showed that the median time to reaching minimal-to-no period pain was about eight weeks. Non-menstrual pelvic pain took considerably longer, with a median around 28 to 32 weeks to reach that same threshold.⁶ If you are considering Myfembree for endometriosis, the period-pain improvement tends to come relatively quickly, but relief from the more diffuse, day-to-day pelvic pain requires patience.

What Two Years of Use Looks Like

One of the common anxieties about hormonal treatments is whether the benefits hold up over time or fade. The SPIRIT open-label extension followed women on Myfembree out to two years. At week 104, about 85% still met the responder threshold for period pain and about 76% for non-menstrual pelvic pain. Pain from intercourse (dyspareunia) and functional quality-of-life scores also held steady. By the end of the two-year mark, 91% of participants were opioid-free and 75% were free of any analgesic.⁷

The bone-density question also gets relevant data from this extension. After a small initial bone mineral density loss of less than 1% at week 24, bone density plateaued by around week 36 and stayed stable through the full two years of treatment.⁸ That modest, self-limiting dip is a meaningful improvement over older GnRH agonists, which could cause progressive bone thinning that limited treatment to six months. It is, however, something your doctor will want to monitor, and longer-term data beyond two years remain limited.

Side Effects and Safety Signals

The add-back estrogen and progestin in Myfembree were specifically designed to blunt the hot flashes and bone loss that plagued earlier hormone-suppressing drugs. Compared to elagolix (sold as Orilissa), a different GnRH antagonist used for endometriosis, post-marketing safety data from the FDA’s adverse event reporting system showed that elagolix carried stronger signals for hot flashes and night sweats than Myfembree.⁹ That difference aligns with the design rationale: the add-back therapy in Myfembree is doing what it was intended to do.

Blood clots are the safety concern that gets the most attention, and rightly so. A disproportionality analysis of post-marketing reports found signals for deep vein thrombosis, pulmonary embolism, and blood pressure increases. These events were less frequent than bleeding-related reports but clinically serious. Among cases with trackable dates, the median time to onset was about 19 days, with many vascular events occurring in the first few weeks after starting treatment.¹⁰ This early clustering suggests the initial adjustment period carries the highest risk, and it is why Myfembree carries warnings about use in women with a history of blood clots or certain cardiovascular risk factors.

One area worth flagging is psychiatric side effects. In the FAERS comparison study, elagolix showed a disproportionate signal for suicidal ideation, and both elagolix and Myfembree had basic-level signals for depression, anxiety, and mood swings, though these did not reach the threshold for robust disproportionality.¹¹ Post-marketing reporting databases have real limitations: they capture what gets reported, not what actually happens at a fixed rate. Still, if you have a history of mood disorders, this is a conversation to have with your prescriber before starting.

What Myfembree Does Not Do to Fibroids

Here is one of the biggest disconnects between what people hope the drug will do and what it actually does. Myfembree is excellent at managing symptoms, particularly heavy bleeding, but it does not meaningfully shrink fibroids. In the LIBERTY long-term extension, uterine volume decreased by about 13% at 24 weeks and 14% at one year, while individual fibroid volume dropped by roughly 14% at 24 weeks and 18% at one year.¹² These are modest changes. A review of GnRH antagonist combination therapies found no clinically meaningful volume reductions overall.¹³

This matters for expectation-setting. If your primary problem is heavy bleeding and pain, Myfembree can be very effective at controlling those symptoms even while the fibroids themselves remain roughly the same size. But if your fibroids are causing bulk symptoms like pressure on your bladder, frequent urination, or a visibly enlarged abdomen, the drug is unlikely to resolve those complaints because it is not substantially reducing the physical mass. Understanding this distinction helps you and your doctor decide whether Myfembree is the right tool for your particular situation or whether a procedural approach would serve you better.

Can It Delay or Replace Surgery?

For women facing a hysterectomy or myomectomy, Myfembree sometimes enters the picture as a bridge or even an alternative. Real-world data from an observational study found that among 31 women who had been flagged for surgery, none had undergone the procedure by the six-month follow-up after starting relugolix combination therapy. The authors noted that improvements in bleeding occurred regardless of whether the patient had originally been referred for medical management or surgery, raising the question of whether some women initially on a surgical track might reconsider after experiencing symptom relief.¹⁴

That said, the drug does not eliminate the need for surgery in every case. A separate real-world study tracking women on Myfembree alone found that four still underwent hysterectomy. One was a non-responder whose bleeding remained heavy, one stopped treatment due to a phlebitis complication, and two others achieved partial improvement but ultimately chose surgery over continuing a daily pill indefinitely.¹⁵ The takeaway is that Myfembree can buy meaningful time and may genuinely replace surgery for some women, but it is not a universal substitute, and personal preferences about daily medication versus a one-time procedure play into the decision as much as the clinical results do.

Real-World Experience Versus Trial Results

Clinical trials select carefully. Participants tend to be motivated, closely monitored, and screened to exclude conditions that might complicate results. Real-world patients are messier: they miss doses, they have comorbidities, they stop treatment because of cost or side effects that would not have triggered a formal adverse-event report. That gap explains why online patient reviews tend to be more mixed than trial data suggests.

The real-world observational study mentioned above confirmed that bleeding improvements did occur outside the controlled trial setting, which is reassuring.¹⁶ But discontinuation is a real phenomenon. Some women stop because the drug works and they feel better; others stop because side effects outweigh benefits, insurance changes, or they simply do not want to take a daily pill for an indefinite stretch. If you are reading online reviews, keep in mind that people who quietly continue a medication that works tend not to post about it, while those who have a bad experience are more motivated to share. This skews the anecdotal picture more negative than the average experience probably is.

Cost and Practical Access

Myfembree is not cheap. In the UK, the list price is about £72 for a 28-day pack, working out to roughly £939 per year. The UK’s National Institute for Health and Care Excellence (NICE) has evaluated it as cost-effective for moderate to severe fibroid symptoms in reproductive-age adults.¹⁷ In the United States, the cost is typically higher and varies widely depending on insurance coverage, manufacturer coupons, and pharmacy. Many women report that the copay assistance programs offered by the manufacturer make the difference between affording it and not.

One practical advantage Myfembree has over some competitors is that the add-back therapy is built into the same pill. Other GnRH antagonists may require a separate prescription for estrogen and progestin add-back, adding cost and complexity. A single-tablet combination simplifies the regimen and tends to be less expensive than two separate prescriptions.¹⁸ If you are comparing options with your provider, this is a practical detail worth weighing alongside clinical outcomes.

Fertility and Contraception Considerations

Myfembree suppresses ovulation while you are taking it, but it is not approved as a contraceptive. Ovulation can return quickly after stopping, and the drug is not recommended during pregnancy. If you are trying to conceive in the near future, the treatment is generally framed as something you would use to manage symptoms and then discontinue when you are ready to try for pregnancy. If you are not trying to conceive, you still need reliable contraception, because breakthrough ovulation is possible, and the hormonal components of the pill could pose risks to a developing pregnancy. This is a point that sometimes gets lost in discussions focused on symptom relief.

For women with fibroids who are specifically delaying surgery in hopes of preserving fertility, Myfembree can serve as a temporizing strategy. It controls bleeding and can improve anemia, potentially putting you in better shape for a future myomectomy or pregnancy. But because it does not substantially shrink the fibroids themselves, it does not remove the structural issue that may be complicating fertility in the first place.

How Myfembree Compares to Older Treatments

Before GnRH antagonist combination therapies, the standard hormonal options for fibroids and endometriosis included GnRH agonists (like leuprolide), progestin-only pills, hormonal IUDs, and combined oral contraceptives. GnRH agonists suppressed estrogen effectively but without add-back therapy were limited to about six months of use due to bone loss and menopause-like symptoms. Myfembree’s built-in add-back therapy addresses this directly, and the two-year extension data show bone density stabilizing after a small initial dip.¹⁹

Compared to elagolix, the other GnRH antagonist available for endometriosis in the U.S., Myfembree’s integrated add-back design appears to reduce the burden of hot flashes and night sweats, based on post-marketing safety reporting.²⁰ The convenience of a single daily pill versus elagolix’s twice-daily dosing (at its higher dose) is another practical advantage. None of this means Myfembree is the right choice for everyone. Hormonal IUDs, for instance, offer localized progestin delivery with fewer systemic effects and work well for many women with heavy bleeding. The right treatment depends on your specific symptoms, your tolerance for side effects, whether you want to preserve fertility, and your financial situation.